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Abstract
Background: In chronic obstructive pulmonary disease (COPD), the response of the forced expiratory volume in 1 
second (FEV1) after bronchodilator application is weak. Inspiratory parameters like the forced inspiratory volume in 1 
second (FIV1) and inspiratory capacity (IC) can be responsive to bronchodilators. In an individual patient with COPD, a 
significant bronchodilator response must at least exceed the random variation for that parameter. Therefore, it is 
important that the type of scatter is homoscedastic, as the chance of underestimating or overestimating the random 
variation for low or high parameter values is minimized. The aim of this study is to investigate the random variation 
(type and quantity) of inspiratory parameters.
Methods: In 79 stable COPD patients, spirometry was performed.
The forced inspiratory volume in 1 second (FIV1), inspiratory capacity (IC), maximal inspiratory flow at 50% (MIF50)
and peak inspiratory flow (PIF) were measured five times in one day and again within two weeks of the first
measurement. The values of these parameters, taken within one hour, within one day and between two different
days, were compared. The coefficient of repeatability (CR) was calculated, and, in addition, linear regression was
performed to investigate the type of scatter (homo- or heteroscedastic) of the measured parameters.
Results: The type of scatter was heteroscedastic for all of the parameters when the differences were expressed as 
absolute values; however, when the differences were expressed as the percent change from the initial values, we found 
a more homoscedastic scatter. The CR within one hour of each parameter expressed as the percent change from the 
initial value was: IC, 19%; FIV1, 14%; PIF, 18%; MEF50, 21%.
Conclusions: To obtain a more homoscedastic scatter, percentage changes in FIV1, IC and MIF50 are more appropriate 
than absolute changes.
In an individual patient with COPD, a significant improvement for a particular parameter must at least exceed the 
above-mentioned CR.
Background
The severity of chronic obstructive pulmonary disease
(COPD) is defined by the degree of expiratory airflow
limitation. It is essential for diagnosis and provides a use-
ful description of the severity of pathological changes in
COPD [1]. It is, however, well known that the correlation
between the subjective improvements in dyspnea and the
increases in Forced Expiratory Volume in 1 second
(FEV1) after inhalation of bronchodilators is low [2-4].
Many COPD patients do not show significant revers-
ibility of FEV1 after bronchodilators, as defined by a 12%
improvement from the initial value and at least 200 ml
[5], but may experience less dyspnea from their use.
Taube and co-workers [4] demonstrated that this change
in dyspnea may be related to improvements in inspiratory
flow rates. These authors found that in patients with
severe COPD (FEV1 mean was 38% of the predicted nor-
mal value), the reduction in dyspnea after the inhalation
of a beta (2)-adrenoreceptor agonist was closely corre-
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lated to the change in parameters of forced inspiration,
particularly for the forced inspiratory volume in 1 second
(FIV1), but not with changes in parameters of forced
expiration. They also concluded that, "In less severe
COPD or asthma, the reduction in dyspnea was associ-
ated with the improvements in both FIV1 and FEV1, but
in severe COPD with the improvement in FIV1 only" [6].
O'Donnell et al. found a correlation between the change
of the Inspiratory Capacity (IC) after bronchodilator
administration, dyspnea and duration of exercise [7,8]. In
2005, a published ATS/ERS statement on clinical pulmo-
nary function testing [9] made no recommendations on
the measurement of inspiratory parameters including
FIV1. Therefore, it is unclear how FIV1 and other inspira-
tory parameters should be measured and which improve-
ments in a patient are beyond random variation for these
parameters after the use of bronchodilators or other
interventions.
How FIV1 should be measured in patients with COPD
was the subject of a previous study by our group. We
found that the optimal FIV1 was obtained immediately
after a slow expiration (in contrast to a forced expiration)
and that at least five forced inspiratory maneuvers should
be performed [10].
However, there is no clear consensus about how to
express reversibility in subjects with airflow limitation
[5]. The two most commonly described methods are the
percent change of the initial value and the absolute
change in the parameter value. As the percent change
from the initial value is too sensitive at very low values, as
measured in severe obstructive patients, a third method
uses the percent change from the predicted normal value
[5]. For the inspiratory parameters under study, no
accepted predicted normal values are available; hence, we
used the first two methods.
For an individual patient with COPD, a significant
bronchodilator response must at least exceed the random
variation for the parameter of interest. Therefore, it is
important to know which type of variation or scatter
exists for that parameter. Figure 1 shows a theoretical
dataset of a test-retest lung-function parameter with dif-
ferent types of scatter. In the left panel, we made the
amount of scatter the same for each value of the parame-
ter, called "homoscedastic" scatter. For the whole range of
the parameter, we can use the same value for the random
variation, and a difference of more than 0.2 is beyond the
random variation. The same dataset is used in the right
panel, in which the differences are related to the (average)
parameter value (percent difference) but now the amount
of scatter depends on the parameter value: the higher the
value, the less (in this example) scatter or random varia-
tion there is; this type of scatter is called "heteroscedas-
tic". Therefore, it is important to know the type of scatter
of the parameters in which we are interested. A more
homoscedastic scatter is desired when we express the dif-
ferences as absolute differences or as relative to the
parameter value.
The first topic of this study is to investigate which type
of scatter applies to the (absolute and percent) changes in
inspiratory parameters (FIV1, Inspiratory Capacity (IC),
Peak Inspiratory Flow (PIF) and Maximal Inspiratory
Flow at 50% (MIF50)). Next, we determine the coefficient
of repeatability (CR) for the given parameters [5,11].
Methods
A total of 79 (58 male) consecutive patients who met
ATS-ERS [12] criteria for COPD were recruited from our
outpatient clinic. Criteria for inclusion were a patient age
≥ 40 years, a smoker or former smoker (≥10 pack years),
stable disease and an ability to perform lung function
tests. Excluded patients were those on oral corticoster-
oids or antibiotics in the month before inclusion, or those
who had symptomatic heart failure, respiratory diseases
other than COPD, a history of asthma, allergic rhinitis or
active cancer disease (except basal cell carcinoma of the
skin). The study was approved by the Hospital Medical
Ethical Committee, and all patients gave informed con-
sent.
Patients were asked not to use short-term bronchodila-
tors for the six to eight hours prior to the study and long-
term bronchodilators for at least 12 hours before the
study. Tiotropium and theophylline b.i.d. were not
allowed to be used for the 24 hours prior to the spiromet-
ric test.
Before the tests, a 3.00-liter calibration syringe was
used at three different emptying and filling speeds to
check linearity, as recommended by ATS and ERS stan-
dards [9]. The ambient (room) temperature was mea-
sured before each test session so that BTPS corrections
on the flows and volumes were adequately performed.
Lung function tests were performed five times on the
first day (9, 10, 11, 14 and 15 hours) and once at nine
hours within the following two weeks. Between the two
days, the medication did not change. Also, on the second
day the patients were requested to discontinue broncho-
dilators as on day one.
For expiratory parameters, three adequate and accept-
able flow volume curves were produced in accordance
with conventional ATS/ERS criteria [9]. The largest
forced vital capacity (FVC) and FEV1 were recorded. For
the predicted FEV1 and FVC, the normal values of the
European Respiratory Society were used [13].
For inspiratory parameters, five adequate IC measure-
ments and maximal forced inspirations after a slow and
maximal expiration were obtained. Full inspiration was
obtained when a plateau in the flow was reached or after
at least an eight-second duration of the inspiration. Of
these five maneuvers, we took the highest value obtained
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for the FIV1, IC, PIF and MIF50 [10]. IC was measured by
the method described by Hadcroft and Calverly [14]
immediately before each forced inhalation.
If, during the inspiratory maneuvers, the vital capacity
(VC) was reached before the FIV1, then FIV1 = VC.
The flow-volume curves were measured with a V-
MAX20 (Sensor Medics, ViaSys, Conshohocken, PA,
USA).
In order to obtain proper inspiratory parameters after a
slow expiration, we began the measurement during the
slow expiration and stopped the procedure when the
patient reached maximal inspiration; otherwise, the V-
MAX20 software rejects the values obtained.
Analysis
The five intra-day lung function parameter data were
analyzed with the repeated measures ANOVA and Bon-
ferroni's multiple comparison tests.
The type of scatter (homoscedastic or heteroscedastic)
was determined as follows. The differences between each
test and retest value pair versus the average value were
plotted as described by Bland and Altman [11]. Negative
differences were transformed to positive values by taking
the absolute values of the differences. We applied linear
regression of these transformed differences on the aver-
age value of the parameter. When there is a pure homo-
scedastic scatter, the regression line will be close to
horizontal and the slope will not significantly differ from
zero. When there is a heteroscedastic scatter, the slope of
the regression line will be significantly different from
zero. For each parameter, scatter plots were made for
both absolute differences and percentage differences
from the average value. With linear regression, we tested
for the significances of the slopes. Instead of slopes, we
present standardized slopes, i.e., correlation coefficients,
as these can be compared across parameters and meth-
ods.
The coefficient of repeatability (CR), as established
within one hour, intra-day and inter-day, was determined
by the method described by Bland and Altman [11]. The
CR was determined as 1.64 times the standard deviation
of the differences, represented as absolute values or as
percentages of the average values. We performed a one-
tailed test instead of a two-tailed test, as the interventions
we were interested in were expected to improve a param-
eter; hence, we took 1.64 times SD instead of 1.96 × SD.
This use of a one-tailed test is analogous to the way in
which lower limits of normals are calculated [13]. CR was
used instead of the more common coefficient of variation
(CV) because CV does not take into account the type of
scatter that can be visualized by the scatter plots of Bland
and Altman [11].
Results
Seventy-nine patients were included for day one (intra-
day measurements), and 76 were measured again within
Figure 1 Bland and Altman plots with theoretical types of scatter. The vertical axis shows the test (T) retest (R) difference (T-R); the horizontal axis 
shows the average (T+R/2). Each point corresponds with one test-retest pair. Left panel: dataset with a random scatter not dependent on the param-
eter value. Right panel: same dataset, but now the percent change from the average parameter value is shown; the scatter is highly dependent on 
the parameter value. In the left panel, the scatter can be described with just one value, e.g., the coefficient of repeatability (CR). In the right panel, the 
scatter cannot be precisely described with one value because the scatter on the low and high parameter values will not precisely reflect a fixed CR. 
Thus, for describing random variation, a homoscedastic scatter is preferred.
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the following two weeks. For two patients, we were
unable to get an appointment within the two weeks, and
in one there was an exacerbation. The baseline patient
characteristics are summarized in Table 1.
The intra-day mean and SD values did not differ signifi-
cantly (repeated measures ANOVA) on different occa-
sions that day (see Table 2). Therefore, we took three
value pairs per parameter for each patient with a one-
hour difference (9-10, 10-11 and 14-15 hours) for deter-
mination of the type of scatter and the one-hour coeffi-
cient of repeatability.
The type of scatter for the FEV1 and the inspiratory 
parameters FIV1, IC, PIF and MIF
The scatter of differences in IC values versus average IC
value on two occasions in-between one hour is shown in
Figure 2, panel A. The scatter becomes wider when the
average IC increases. Panel B presents the same data,
except that negative difference values are made positive
and a linear regression line is added to the figure. The
regression line is not flat (P < 0.0001), as it would be if the
scatter was independent of the IC (Table 3).
On the other hand, when the difference in IC is
expressed as a percentage of the average IC (Figure 2,
panel C), an evenly distributed scatter can be seen along
the whole range of the average IC. The slope of the linear
regression line is now nearly flat (Figure 2, panel D) and is
not significantly different from zero (Table 3). The other
parameters were investigated in the same way as the IC,
and the results of the linear regression are presented in
Table 3. To visualize the (more homoscedastic) spread,
the scatter plots of the FIV1, IC, MIF50 and PIF
expressed as percentage differences can be seen in Figure
3.
We did not find a flat regression line for either presen-
tation of the parameters (as differences in liters or as per-
centage differences of the average value); however, for all
but the PIF, we found a more flat regression line corre-
sponding to a lower (r) value when the percentage differ-
ence of the average value was used (less significant
difference from zero, as can be seen in Table 3).
The random variability presented by the coefficient of 
repeatability
The coefficients of repeatability for IC, FIV1, MIF50 and
PIF are graphically presented as Bland-Altman plots in
Figure 4, panels A-D. The spread around no difference
(solid line) can be seen, and the coefficient of repeatabil-
ity is presented as the dotted lines ±1.64 × standard devi-
ation. We can also see the relatively even spread around
the solid line, which is an indication of a more homosce-
dastic spread. In patients with COPD, we found that the
one-hour random variabilities expressed as the coeffi-
cients of repeatability (CR) for the lung function parame-
ters are: IC: 19%, FIV1: 14%, PIF: 18% and MEF50: 21%
(Table 4).
In the same way as the one-hour coefficients of repeat-
ability, the intra-day coefficients of repeatability and the
in-between day coefficients of repeatability are investi-
gated.
The intra-day random variabilities expressed as the
coefficients of repeatability (CR) for the lung function
parameters are: IC, 21%; FIV1, 18%; PIF, 18% or 0.90 l/;
and MEF50, 21% (Table 4).
Table 1: Characteristics of the COPD patient group.
Number of subjects 79 Range
Male (%) 58 (73)
Height, m, mean (SD) 1.702 (0.1) 1.49-1.94
Weight, kg, mean (SD) 75.4 (15.9) 39.7-128
BMI, kg/m2, mean (SD) 25.7 (4.96) 18-47
Age, yrs, mean (SD) 65.4 (8.69) 44-83
Current smoker (%) 47 (59)
FEV1, mean (SD) 1.48 (0.70) 0.37-2.65
Predicted FEV1, mean (SD) 2.83 (0.60) 1,26-4.23
FEV1, % predicted, (SD) 48.7 (12.6) 13.5-79.8
GOLD 1 number (%) 13 (17)
GOLD 2 number (%) 24 (30)
GOLD 3 number (%) 28 (35)
GOLD 4 number (%) 14 (18)
COPD = Chronic Obstructive Pulmonary Disease; BMI = Body Mass Index; FEV1 = Forced Expiratory Flow in One second;
GOLD = Global Initiative for Chronic Obstructive Lung Disease (stage 1,2,3 or 4).
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The inter-day random variabilities expressed as the
coefficients of repeatability (CR) for the lung function
parameters are: IC: 23%, FIV1: 14%, PIF: 18% and MEF50:
21% (Table 4).
Discussion
Type of scatter
This study has shown that within the same subject, differ-
ences in lung function parameters (IC, FIV1, MIF50 and
PIF) before and after one hour can more appropriately be
described when taken as the percentages of the initial val-
ues than as differences in the absolute values because of
the more homoscedastic scatter. All measured parame-
ters showed a scatter that was significantly dependent on
the average parameter value and thus is heteroscedastic if
we present the differences in liters or L/sec. On the other
hand, if we represent the difference as the percentage of
the average value (which is nearby the initial value), we
found no significant dependence on the parameter value
for IC and less dependence on the values for the FIV1 and
MIF50.
Several studies have addressed the variability of lung
function parameters, especially on forced expiration [15-
19], but used the variation coefficient instead of the
method described by Bland and Altman [11]. Therefore,
the type of spread was not investigated. In the ATS-ERS
statement, the method of Bland and Altman is described
as the preferred method for investigating the random
variation, and this method makes the type of spread visi-
ble [5,11].
The only exception is the PIF, which displays a slightly
steeper slope when expressed as the percentage differ-
ence.
Random variability
The one-hour repeatability is by far the most important
random variability because most interventions we are
interested in, such as bronchodilator response, can be
measured within one hour. Subjects must at least exceed
this random variation before it can be decided that an
improvement of an intervention can be attributed to that
intervention. We did not find any CR for inspiratory
parameters in the literature.
Table 2: Mean and (SD) values of lung function parameters on five occasions during the day
Parameter/time 9 10 11 14 15
FEV1 1.48 (0.70) 1.48 (0.69) 1.48 (0.90) 1.48 (0.70) 1.41 (0.68)
FIV1 2.70 (0.85) 2.71 (0.87) 2.69 (0.87) 2.65 (0.84) 2.62 (0.81)
IC 2.13 (0.69) 2.15 (0.68) 2.17 (0.72) 2.18 (0.75) 2.14 (0.79)
MIF50 4.68 (1.63) 4.61 (1.61) 4.65 (1.62) 4.51 (1.55) 4.47 (1.18)
PIF 4.96 (1.67) 4.92 (1.66) 4.95 (1.67) 4.89 (1.61) 4.84 (1.65)
FEV1 = Forced Expiratory Flow in one second; FIV1 = Forced Inspiratory Flow in One second; IC- Inspiratory Capacity; MIF50 = Maximal 
Inspiratory Flow at 50%; PIF = peak Inspiratory Flow.
Table 3: Linear regression: standardized slopes (r) and P values; tests whether the slope is significantly different from 
zero. N = 237
Parameter Standardized slope (r) P value (significance from zero slope)
FEV1 0.37 <0.0001
%FEV1 0.10 0.1 (NS)
IC 0.27 <0.0001
%IC 0.05 0.46 (NS)
FIV1 0.20 0.002
%FIV1 0.13 0.045
PIF 0.20 0.002
%PIF 0.24 0.0002
MIF50 0.22 0.0009
%MIF50 0.14 0.0267
FEV1 = Forced Expiratory Flow in one second; FIV1 = Forced Inspiratory Flow in One second; IC- Inspiratory Capacity; MIF50 = Maximal 
Inspiratory Flow at 50%; PIF = peak Inspiratory Flow. See also Figures 2 and 3 and the text for further explanation.
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We decided to pool our patients' data (with one-hour
differences measured at three time-points a day per
patient) to obtain more data points and, thus, more reli-
able results. This pooling was possible because we found
no significant differences between the group means and
spreads and no significant differences of the parameters
between the measurements between 9 a.m. and 2 p.m.
This result is in contrast with Calverley et al. [20] and van
Noord et al. [21], who found significantly lower values at
3 and 6 a.m.; however, we did not measure at these hours.
We chose the CR instead of the more popular variation
coefficient because it more precisely reflects the repeat-
ability and provides a graphical representation of the type
of scatter, as stated by Bland and Altman [11] and the rec-
ommendations of the ERS-ATS committee [5].
The CR for the PIF is less than that for the MIF50
which may be because the MIF50 is situated near the PIF
in maximal inspiratory flow volume curves but is seldom
exactly aligned; thus, the MIF50 demonstrated more
spread.
Whether PIF improvement is therefore more sensitive
to bronchodilators than PIF is not answered by this study.
The intra-day coefficients of repeatability are impor-
tant to know when we are performing interventions that
take more than one hour, i.e., medications such as theo-
phylline, tiotroprium or other interventions that take
more time to retest.
We selected the 9-to-14-hour difference because all
parameters as group means did not change during this
interval. There was a small but significant decrease in
some parameters (FEV1 and MIF50) on the 9-to-15-hour
interval; therefore, we took the 9-to-14 as our difference.
We think that this decrease in some parameter values
may be due to the fact that patients at the end become
tired of repeating this procedure five times a day, during
which time they were not allowed to take any bronchodi-
lator drugs, or that there may be some circadian effect
[20,21]. The higher intraday CR value, than the one hour
CR value, could be expected because of the greater time
interval.
Improvements of interventions taking more than one
day can be considered as beyond random variation when
the inter-day coefficients of repeatability are taken into
account. Between the two days, patients did not change
Figure 2 Panel A: Bland-Altman plot showing the absolute difference of Inspiratory Capacity (IC) versus the average; it shows a heterosce-
dastic scatter of the IC. Panel B: Absolute difference of IC versus average IC plus linear regression; this panel shows a slope in the regression line. Panel 
C: Difference IC now presented as the percentage of the average value; this panel shows a homoscedastic scatter. Panel D: Percentage difference of 
IC versus average IC plus linear regression; this panel shows a flat slope of the regression line, not significantly different from zero. The dashed lines in 
panel B and D represent the confidence interval of the regression line.
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their medication and no exacerbations occurred. A weak
point of these CR is that we were unable to see all patients
on an exact inter-day interval of one week because we
were dependent on when our patients were able to visit
our outpatient department again. As the smallest interval
was three days, and the greatest interval was eight days,
the analyses were all conducted within two weeks. In gen-
eral, the longer the interval between the two measure-
ments (from one hour to several days), the greater the CR
obtained. This result may be caused by the longer time
period for weather to influence the patients or other
effects of irritants in the environment.
Figure 3 Left panels show the scatter (absolute differences and regression lines for FIV1, MIF50 and PIF). Right panels show the percentage 
differences for the same parameters. The dashed lines represent the confidence intervals of the regression lines. All slopes of the regression lines are 
significantly deviated from flat (zero); however, apart from the PIF, the percentage differences show regression lines that are more flat (closer to a zero 
slope). FIV1 = Forced Inspiratory Flow in One second; MIF50 = Maximal Inspiratory Flow at 50%; PIF = peak Inspiratory Flow.
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Table 4: Coefficients of repeatability (CR) retested after one hour (n = 237), after five hours (n = 79) and after 3-10 days (n-
76) (in % from initial value/absolute value)
Parameter Retest after one hour Retest after five hours Retest another day
FEV1 11.8 13.7 17.9
IC 18.9 21.3 22.7
FIV1 13.5 17.9 18.0
PIF 17.9 17.8/0.90 17.9/0.85
MIF50 20.4 21.0 19.2
FEV1 = Forced Expiratory Flow in one second; FIV1 = Forced Inspiratory Flow in One second; IC- Inspiratory Capacity; MIF50 = Maximal 
Inspiratory Flow at 50%; PIF = peak Inspiratory Flow.
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Similar to the one-hour and intra-day random varia-
tion, we were unable to find the inter-day random varia-
tion on inspiratory parameters in the literature.
Limitations of this study:
The subjects in this study include the investigation of
only patients with COPD, so it does not extend to normal
patients or those with asthma or restrictive disease. The
random variation in these groups may be different.
The type of scatter was only examined after one hour,
and it may be different when other intervals are taken
into account.
The wash-out time for Tiotropium was 24 hours,
although some investigators used 48 hours for this drug.
We think this 24 hours time period had limited influence
on the test-retest results.
We used all data including the outliers to construct the
Bland and Altman plots; in small samples, this can influ-
ence the linear regression of the transformed Bland and
Altman plots when the outliers are in the lower or upper
zones of the average parameter value.
Conclusions
Differences in lung function parameters (IC, FIV1, MIF50
and PIF) are described with less dependence on the
parameter values when taken as percentages from the ini-
tial values than as absolute difference values.
The random variation expressed as coefficients of
repeatability for several time intervals are presented.
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